List view / Grid view
In this article, Dr Harsh Shah and colleagues summarise their research into the importance of characterising physicochemical characteristics that can result in stress-induced solid-state changes in Narrow Therapeutic Index (NTI) drugs.
Results of a study suggest the need for caution in the prescription of direct oral anticoagulants for patients with chronic kidney disease, due to the risk of bleeding...
Direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a new study.
Blood-thinning drugs not only reduce the risk of stroke in patients with AF but are also associated with a significant reduction in the risk of dementia...
A study has found that a new group of drugs used to treat patients with serious blood clots are not associated with a higher risk of major bleeding compared with warfarin...
Researchers have found that using just two anti-clotting medicines for atrial fibrillation is safer than using the current standard treatments...
10 December 2013 | By Daiichi Sankyo Company
This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
20 November 2013 | By Daiichi Sankyo Europe
Once-daily edoxaban, evaluated in two treatment arms achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism...
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
28 August 2011 | By Bristol-Myers Squibb Company, Pfizer
Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial...
